1 2 High prevalence of symptoms among Brazilian subjects with antibodies against 3 SARS-CoV-2: a nationwide household survey. 4 Ana M B Menezes anamene.epi@gmail.com 0000-0002-2996-9427 5 6 Cesar G Victora cvictora@gmail.com 0000-0002-2465-2180 7 Fernando P Hartwig fernandophratwig@gmail.com 0000-0003-3729-0710 8 Mariângela F Silveira mariangelafreitassilveira@gmail.com 0000-0002-2861-7139 Bernardo L Horta <u>blhorta@gmail.com</u> 0000-0001-9843-412X 9 10 Aluísio J D Barros abarros.epi@gmail.com 0000-0002-2022-8729 11 Marilia A Mesenburg mariliaepi@gmail.com 0000-0001-9598-4193 12 Fernando C Whermeister fewehrmeister@gmail.com 0000-0001-7137-1747 13 Lúcia C Pellanda <u>pellanda@ufcspa.edu.br</u> 0000-0002-4593-3416 14 Odir A Dellagostin odirad@gmail.com 0000-0003-2803-4088 15 Cláudio José Struchiner claustru@gmail.com 0000-0003-2114-847X 16 Marcelo N Burattini mnburatt@gmail.com 0000-0002-5407-6890 17 Fernando C Barros febarros.epi@gmail.com 0000-0001-5973-1746 Pedro C Hallal prchallal@gmail.com 0000-0003-1470-6461 18 19 20 Universidade Federal de Pelotas, Brazil (Prof. Ana M B Menezes, Prof. Bernardo L 21 Horta, Dr. Fernando P Hartwig, Dr. Fernando C Wehrmeister, Prof. Mariângela F 22 Silveira, Dr. Marilia A Mesenburg, Prof. Aluísio J D Barros, Prof. Odir A Dellagostin, Prof. Fernando C Barros, Prof. Cesar G Victora, Dr. Pedro C Hallal), Fundação 23 24 Universidade Federal de Ciências de Saúde de Porto Alegre, Brazil (Dr. Marilia A

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

Mesenburg, Prof. Lúcia C Pellanda), Fundação Getúlio Vargas, Brazil (Prof. Claudio J Struchiner), Universidade de São Paulo, Brazil (Prof. Marcelo N Burattini) **ABSTRACT** Since the beginning of the pandemic of COVID-19, there has been a widespread assumption that most infected persons are asymptomatic. A frequently-cited early study from China suggested that 86% of all infections were undocumented, which was used as indirect evidence that patients were asymptomatic. Using data from the most recent wave of the EPICOVID19 study, a nationwide household-based survey including 133 cities from all states of Brazil, we estimated the proportion of people with and without antibodies for SARS-CoV-2 who were asymptomatic, which symptoms were most frequently reported, the number of symptoms reported and the association between symptomatology and sociodemographic characteristics. We were able to test 33,205 subjects using a rapid antibody test that was previously validated. Information on symptoms was collected before participants received the test result. Out of 849 (2.7%) participants who tested positive for SARS-CoV-2 antibodies, only 12.1% (95%CI 10.1-14.5) reported no symptoms since the start of the pandemic, compared to 42.2% (95%CI 41.7-42.8) among those who tested negative. The largest difference between the two groups was observed for changes in smell or taste (56.5% versus 9.1%, a 6.2-fold difference). Symptoms change in smell or taste, fever and myalgia were most likely to predict positive test results as suggested by recursive partitioning tree analysis. Among individuals without any of these three symptoms (74.2% of the sample), only 0.8% tested positive, compared to 18.3% of those with both fever and changes in smell

- 50 or taste. Most subjects with antibodies against SARS-CoV-2 in Brazil are symptomatic,
- even though most present only mild symptoms. 51

INTRODUCTION

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

Since the beginning of the pandemic of COVID-19, there is a widespread notion that most people infected by SARS-CoV-2 are asymptomatic, following an early article from China stating that 86% of those infected did not report any symptoms. 1 More recently, several clinical studies became available, showing that the prevalence of asymptomatic infected individuals ranges from 4% to 75%. <sup>2-6</sup> These discrepancies might be explained by the use of different lists of symptoms, different recall periods, as well as different populations. Population-based studies are particularly relevant for studying SARS-CoV-2 symptoms, because asymptomatic patients or those with mild symptoms may be identified at home, rather than in health service-based studies. Using data from the most recent wave of the EPICOVID19 study, a nationwide household-based survey including 133 cities from all states of Brazil, we estimate the proportion of people with and without antibodies for SARS-CoV-2 who were asymptomatic. We investigated which symptoms were most frequently reported, how many symptoms were reported by each subject, and the associations between symptoms and sociodemographic characteristics. We also performed conditional inference tree analyses using binary recursive partitioning to identify which combinations of symptoms were most likely to predict positive test results. **METHODS** EPICOVID19 is a nationwide seroprevalence survey conducted in sentinel cities in 26 Brazilian states and the Federal District. The Brazilian Institute of Geography and Statistics (IBGE) divides the country into 133 intermediate regions, and the most populous municipality in each region was included in the sample. So far, the study has

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

entailed three waves of data collection (May 14-21, June 4-7, and June 21-24). Here we report on findings from the third wave of data collection which included a detailed investigation of symptoms. A multi-stage probabilistic sample was adopted, with 25 census tracts selected in each one of the 133 sentinel cities, with probability proportionate to size. In each sampled tract, 10 households were systematically selected, totaling 250 households per municipality. All household residents were listed, and age and sex recorded on a list. One individual was then randomly selected as the respondent for that household. Then, a finger prick blood sample was obtained and a questionnaire applied. If the selected subject did not accept to participate, a second resident was randomly chosen. In case of another refusal, the interviewers moved to the next household to the right of the one that had been originally selected. The total planned sample size was 33,250 individuals. The WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China) was used for the detection of antibodies for SARS-CoV-2 (https://en.wondfo.com.cn/product/wondfo-sars-cov-2-antibody-test-lateral-flowmethod-2/); this rapid point-of-care test is based on the principle of immune assay of lateral flow and detects IgG/IgM antibodies against SARS-CoV-2. The presence of antibodies is detected by two drops of blood from a pinprick sample; after the introduction of the blood sample, valid tests are identified by a positive control line in the kit's window; if this control line is not visible, the test is considered inconclusive. A second line also appears in the window if SARS-CoV-2-reactive antibodies are present; in the absence of antibodies, this line is not visible. This rapid test underwent independent validation studies; by pooling the results from the four validation studies,

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

weighted by sample sizes, sensitivity was estimated at 84.8% (95% CI 81.4%;87.8%) and specificity at 99.95% (95% CI 97.8%;99.7%).8-10 Field workers used tablets to record the full interviews, registered all answers, and photographed the test results. All positive or inconclusive tests were read by a second observer, as well as 20% of the negative tests. Subjects were asked about presence (yes/no) of 11 symptoms since March 2020, when the first cases were reported in Brazil: fever, sore throat, cough, difficulty breathing, palpitation, change in smell or taste, diarrhea, vomiting, myalgia, shivering and headache. Subjects were classified as "asymptomatic" if they answered "no" for all symptoms. Sociodemographic variables were also investigated: sex, age in years, schooling (last year completed/grade; recoded as primary or less; secondary; university or higher), selfreported skin color, and household assets. The official Brazilian classification of ethnicity recognizes five groups, based on the question: "What is your race or color?" The five response options are "white", "brown" ("pardo" in Portuguese), "black", "yellow" and "indigenous". Interviewers were instructed to check the "yellow" option when the respondent mentions being of Asian descent, and "indigenous" when any of the multiple first nations were mentioned.<sup>11</sup> The wealth index was created based on a list of assets and goods (computer or laptop, internet access, color television, air conditioning equipment, number of vehicles, cable TV, number of bathrooms and number of bedrooms), through a principal component analysis. The first component was extracted and the total sample divided into quintiles weighted by municipality urban population; the first quintile represent the 20% poorest

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

individuals, and the fifth quintile represents the wealthiest 20% in the sample. 12 For the schooling analysis, subjects under 5 years were excluded as they could still be attending school. Interviewers were tested prior to the field work and only those found to be negative for the virus could participate in the study. Biological safety measures were taken to protect the health of the field workers and individual protection equipment was discarded after visiting each household. Ethical approval was provided by the Brazilian's National Ethics Committee (process number: 30721520.7.1001.5313). Study participants were informed about the objectives of the study, possible risks and advantages. Blood collection took place after obtaining written informed consent from participants or their legal guardians. Individuals testing positive were referred to the statewide COVID-19 surveillance system. In case of a positive rapid test by the respondent, all other residents of the household were also tested for antibodies. The prevalence of each of the 11 symptoms was calculated separately for individuals who tested positive and those with negative results. Means and standard errors (SE) were estimated for the variable on number of symptoms. Prevalence ratio and 95% confidence interval (95% CI) were calculated for each symptom, by dividing the frequency of each symptom in positive and negative subjects. Chi-squared test for heterogeneity or linear trend were calculated, according to the type of variable studied, and interactions with the test result were also tested. Subjects with previous diagnosis of COVID-19 (n=242) and missing information on symptoms (n=1,104) were excluded from the analysis.

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

We also performed conditional inference tree analyses using binary recursive partitioning, accounting for multiple testing<sup>13</sup>. The objective of these analyses was to identify which combinations of the 11 symptoms were most likely to predict positive test results. Analyses were performed using the software Stata version 14.1 (StataCorp, College Station, TX, USA) and conditional inference tree analyses were performed using R 3.6.1 (https://www.r-project.org/). Data will become publicly available 30 days after completion of the fieldwork at <a href="http://www.epicovid19brasil.org/">http://www.epicovid19brasil.org/</a>. **RESULTS** Of the target sample size comprising 33,250 individuals, we were able to include 33,205 (99.9%) participants in the study (missing information for 45 subjects). To achieve this number, a total of 59,724 houses were contacted, with 19.8% of refusals and 24.6% of houses being empty at the time of the visit. Of the 31,869 participants included (after excluding for missing on symptoms and previous COVI-19 diagnosis), 849 subjects (2.7%) tested positive for SARS-CoV-2 antibodies. Test results were only disclosed after the interview on symptoms had been completed. Table 1 shows the distribution of the sample according to sociodemographic characteristics. Each of the 11 symptoms investigated were significantly (P<0.01) more likely to be reported by those testing positive as compared to those testing negative (Table 2). The most frequently reported symptoms among positive cases were headaches (58.0%), change in smell or taste (56.5%), fever (52.1%), cough (47.7%) and myalgia (44.1%). Table 2 also presents the prevalence ratios for each symptom and the 95% CI according

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

to SARS-CoV-2 antibodies. The largest ratios between positive and negative subjects were observed for change in smell or taste (6.2-fold), fever (4.3-fold), shivering (3.3fold) and myalgia (2.8-fold). The sensitivity and specificity for positive test results, for each symptom, are presented in Supplementary Table. The two symptoms with sensitivity above 50% and specificity above 85% were change in smell or taste, followed by fever. Of the 849 participants who tested positive for SARS-CoV-2 antibodies, only 12.1% (95%CI 10.1-14.5) reported none of the 11 symptoms and were therefore classified as asymptomatic, against 42.2% (95%CI 41.7-42.8) among those who tested negative (Figure 1). The mean (SE) number of symptoms for those who tested positive or negative were 3.91 (0.10) and 1.53 (0.01), respectively. Among those who tested positive, 63.5% had three or more symptoms, compared to 23.0% among those who tested negative. In Figure 2 we present the mean number of symptoms among those who tested positive for SARS-CoV-2 as well as the prevalence of asymptomatic subjects, according to sociodemographic characteristics. The associations with ethnicity and household wealth were not significant. Symptoms were more frequent among women than men, and less frequent among individuals with primary or less schooling compared to those with secondary or higher education. The age distribution for the number of symptoms showed in inverse U-shaped pattern, with highest value at ages 30-39 years and the lowest means in children and adolescents. The corresponding figure for individuals without antibodies is included in the supplementary materials (Supplementary Figure 1).

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

Figure 3 displays the results of the conditional inference tree analysis. Out of the 11 symptoms, this analysis selected three: change in smell or taste, fever and myalgia. Given the low overall seroprevalence, in all terminal nodes the prevalence was lower than 20%. Notably, the two thirds of the total sample who reported none of the three symptoms presented a markedly low seroprevalence of 0.8%, compared to 18.3% among those presenting fever, myalgia and change in smell or taste. When an individual tested positive, we also tested other family members. Of the 90 positive subjects with at least one positive family member, 6.7% were asymptomatic, compared to 13.0% asymptomatic among 747 positive subjects without any positive family members (chi-squared = 2.97; P = 0.085). Lastly, we verified whether antibody prevalence levels in cities were associated with the frequency of symptoms among positive subjects, and found no such association (Supplementary Figure 2). **DISCUSSION** In the first two waves of the EPICOVID19 nationwide survey, we identified that, contrary to what is often reported, most subjects with antibodies were symptomatic. However, symptoms had only been assessed for those with positive tests, and the information was collected after the individual had learned about the test result. We addressed the possibility of bias by asking all participants, regardless of the test result, in the third wave. The question on symptoms covered the four-month period since the first COVID-19 cases were reported in the country. The questionnaire was applied before the test result was known, so that respondents were blind to their serological status, and this allowed us to compare symptoms among those testing positive and those

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

testing negative. Subjects with a previous diagnosis of COVID-19 and missing information for symptoms (0.73% of the whole sample) were excluded from the analyses in order to ensure that the respondents were not aware of their condition. The above results from the third wave of the study confirmed a high prevalence of symptoms using a 4-month recall period; only 12.1% positive subjects were asymptomatic, compared to 42.2% of those without antibodies. Inclusion in our analyses of individuals who tested negative was useful for identifying which symptoms were most strongly associated with the presence of antibodies. For example, headaches were the most common symptom affecting 58.0% of those positive, but were also reported by 35.5% of those who tested negative, a prevalence ratio of only 1.6. In contrast, changes in smell or taste affected 56.5% among those who tested positive and 9.1% in the negative ones, respectively. This symptom provided the best discrimination, with a prevalence ratio of 6.2. Recent studies have shown that when SARS-CoV-2 enters the nasal and oral epithelium through the angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), it may cause damages to olfactory and gustatory receptor cells resulting in anosmia or ageusia<sup>14, 15</sup>. Overall, symptoms were more frequent among females than males, in subjects aged 30-29 years and in those with higher education. Children and adolescents were substantially less likely to report symptoms than adults, which is compatible with the lower infection-fatality rates observed in these age groups 16. In contrast, prevalence of symptoms fell with age from 30 to over 70 years, which does not reflect the age pattern in infection-fatality and case-fatality<sup>17</sup>. The difference in reported symptoms between women and men is also at odds with the higher case-fatality among males<sup>18</sup>.

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

Comparison of our findings on the prevalence of symptoms with the literature are affected by the settings in which studies were done, by the phase of infection, the duration of recall, and by the ways in which symptoms were recorded, as well as whether or not the subjects were aware or suspicious of being infected. The prevalence for asymptomatic subjects in the literature ranges from 4% to 75%<sup>2-6, 19, 20</sup>, whereas in our study it was 12.1%. We identified five published reviews that provided pooled prevalence estimates for symptoms<sup>4, 5, 21-23</sup> among individuals who tested positive in health facilities. We found lower prevalence (52.1%) for fever (pooled prevalence ranging from 78.4% to 92.8%) and cough (47.7% versus pooled prevalence ranging from 58.3% to 72.2%). Our estimates for myalgia (44.1%) and difficulty breathing (23.1%) were within the ranges reported in the studies (29.4% to 51.0%, and 20.6% to 45.6%, respectively). Lastly, prevalence of headache in our study (58%) was considerably higher than in the reviews (8.0% to 14.0%). One may assume the prevalence ranges of symptoms based on individuals who sought care in medical facilities would tend to be higher than in our population-based survey, but this was not the case, except for fever or cough. Notably, change in smell or taste was not investigated in these review papers. We searched the literature and change in smell or taste or anosmia/ ageusia was identified in a multicenter European study with prevalence of 85.6% (anosmia) and 88.0% (ageusia)<sup>24</sup> and a very low prevalence in a retrospective study in China (5.1% for hyposmia and 5.6% for hypogeusia)<sup>25</sup>, whereas we found 56.5%. Besides the aforementioned symptoms, some studies have hypothesized that the angiotensin-converting enzyme 2 receptor (ACE2) is also expressed in the mucosa of

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

the gastrointestinal (GI) tract and play lead to GI manifestations<sup>26</sup>. The pooled prevalence of GI symptoms has ranged in the literature from 7.4 to 12.5% for diarrhea (against 25.6% in our study), and 4.6% to 10.2% for nausea and/or vomiting (compared to 9.5% in our study)<sup>26-28</sup>. It is likely that the information on symptoms from population-based studies, such as the one from Spain<sup>29</sup>, would be comparable to our study; however, the recall time in that study was two weeks, compared to up to four months in our survey. In this study, the only symptom specifically reported was anosmia, that was present around 27% of positive subjects, in the three waves. The decision tree analyses were useful for identifying a subgroup of individuals who presented both fever and change in smell or taste, among whom seroprevalence was 18.3%, compared to only 0.8% among subjects that did not present these two symptoms, nor presented body aches. It is clear from the literature that no single symptom correlates perfectly with SARS-CoV-2 infection, thus raising the possibility that the use of multiple symptoms might be appropriate for screening purposes. However, the literature on this topic is still scarce. A study using app-based self-reported data in the United States and in the United Kingdom identified that change in smell or taste is the single symptom most strongly correlated with infection and, using stepwise logistic regression, identified a prediction model that also includes fatigue, persistent cough and loss of appetite<sup>30</sup>. We also identified change in smell or taste as the single most predictive symptom, but the two additional symptoms prioritized in the conditional inference tree analysis were fever and myalgia. Given that the symptoms are partially correlated to one another, it is possible that models including different symptoms yield similar predictions, and would therefore be of similar practical use. Another app-based study including mostly individuals in the United Kingdom identified that, collectively, symptoms improve predicting prognosis<sup>31</sup>. This indicates that symptoms may be used not only for screening, but also for patient

monitoring and planning health service needs.

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

Our study has limitations. Differentiation recall bias is a concern, particularly by using a 4-month recall period, but the alternative – as in the Spanish survey – was to ask for symptoms in a shorter, more recent period and potentially misclassifying individuals who had the disease in the past, and for whom antibodies remained detectable. In order to evaluate the likelihood of differential recall bias, we excluded the 242 participants who had a diagnosis of COVID-19 prior to the interview. Another limitation is the growing evidence that antibody levels decrease rapidly over time, for example by 14% in the same subjects in the Spanish study<sup>29</sup>, and in our own (unpublished) analyses comparing the first and third waves of the survey in cities with high initial prevalence. This would lead some individuals who had the disease to test negative, and yet report symptoms that occurred at the time of the episode. This type of bias would reduce the difference in reported symptoms among subjects who tested positive and negative. An additional limitation is the growing evidence that antibody levels decrease rapidly over time, for example by 14% in the same subjects in the Spanish study<sup>28</sup>, and in our own (unpublished) analyses comparing the first and third waves of the survey in cities with high initial prevalence. This would lead some individuals who had the disease to test negative, and yet report symptoms that occurred at the time of the episode. This

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

perpetuity.

It is made available under a CC-BY-NC 4.0 International license.

characteristic of the dynamics of the infection would reduce the difference in reported symptoms among subjects who tested positive and negative. Positive aspects of our study, on the other hand, included the population basis over an area of 8.5 million square km, the large sample size, collection of symptoms in positive and negative cases, and blinding of respondents as test results were only disclosed after the clinical history was collected. In summary, our analyses show that most individuals with antibodies against SARS-CoV-2 report having presented symptoms, even though in most cases these were mild. Our findings can be used to implement surveillance systems in Brazil, which would help identify cases early and guide testing procedures. Acknowledgments We acknowledge the support from Instituto Serrapilheira, Pastoral da Criança, the Brazilian Collective Health Association (ABRASCO) and JBS's initiative 'Fazer o Bem Faz Bem'. Ana M B Menezes, Cesar G Victora, Fernando P Hartwig, Mariângela F Silveira, Bernardo L Horta, Aluísio J D Barros, Lúcia C Pellanda, Odir A Dellagostin, Claudio J Struchiner, Marcelo Burattini, Fernando C Barros and Pedro C Hallal contributed to the conception and design of the work, to the acquisition, analysis, and interpretation of data and the draft of the manuscript. Marilia A Mesenburg and Fernando C Whermeister contributed to the analysis of data. All authors have approved the submitted version and have agreed to be personally accountable for the author's own

- 353 contributions and to ensure that questions related to the accuracy or integrity of any part
- 354 of the work, even ones in which the author was not personally involved, are
- 355 appropriately investigated, resolved, and the resolution documented in the literature.

## 357 **Competing interests**

358 None declared

356

359

360

## REFERENCES

- 361 Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the 1.
- 362 rapid dissemination of novel coronavirus (SARS-CoV-2). Science.
- 363 2020;368(6490):489-93.
- 364 2. Zhou X, Li Y, Li T, Zhang W. Follow-up of asymptomatic patients with SARS-
- 365 CoV-2 infection. Clin Microbiol Infect. 2020;26(7):957-9.
- 366 3. Day M. Covid-19: identifying and isolating asymptomatic people helped
- 367 eliminate virus in Italian village. BMJ. 2020;368:m1165.
- 368 Zhu J, Zhong Z, Ji P, et al. Clinicopathological characteristics of 8697 patients 4.
- 369 with COVID-19 in China: a meta-analysis. Fam Med Community Health. 2020;8(2).
- 370 5. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease
- 371 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect.
- 372 2020;80(6):656-65.
- 373 Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of 6.
- 374 COVID-19 infections: A systematic review and meta-analysis. Int J Infect Dis. 2020.
- Hallal P, Barros F, Silveira M, et al. EPICOVID19 protocol: repeated 375 7.
- 376 serological surveys on SARS-CoV-2 antibodies in Brazil. 2020 [2020/07/27];

- 377 Available from: http://www.cienciaesaudecoletiva.com.br/artigos/epicovid19-protocol-
- 378 repeated-serological-surveys-on-sars-cov2-antibodies-in-brazil/17691.
- 379 8. Whitman JD, Hiatt J, Mowery CT, et al. Test performance evaluation of SARS-
- 380 CoV-2 serological assays. MedRxiv. 2020.
- 381 9. Horta BL, Gigante DP, Goncalves H, et al. Cohort Profile Update: The 1982
- 382 Pelotas (Brazil) Birth Cohort Study. Int J Epidemiol. 2015;44(2):441, a-e.
- 383 10. Pellanda LC, Wendland EM, McBride AJ, et al. Sensitivity and specificity of a
- 384 rapid test for assessment of exposure to SARS-CoV-2 in a community-based setting in
- 385 Brazil. MedRxiv. 2020.
- 386 11. Petruccelli JL, Saboia AL. Características étnico-raciais da população:
- 387 classificações e identidades: Instituto Brasileiro de Geografia e Estatística--IBGE; 2013.
- 388 Rutstein SO. The DHS wealth index: approaches for rural and urban areas: 12.
- 389 Macro International Incorporated; 2008.
- 390 Hothorn T, Hornik K, Zeileis A. Unbiased Recursive Partitioning: A Conditional 13.
- 391 Inference Framework. Journal of Computational and Graphical Statistics.
- 392 2006;15(3):651-74.
- 393 14. Hoang MP, Kanjanaumporn J, Aeumjaturapat S, et al. Olfactory and gustatory
- 394 dysfunctions in COVID-19 patients: A systematic review and meta-analysis. Asian Pac
- 395 J Allergy Immunol. 2020.
- 396 Butowt R, Bilinska K. SARS-CoV-2: Olfaction, Brain Infection, and the Urgent 15.
- 397 Need for Clinical Samples Allowing Earlier Virus Detection. ACS Chem Neurosci.
- 398 2020;11(9):1200-3.
- 399 16. Yang W, Kandula S, Huynh M, et al. Estimating the infection fatality risk of
- 400 COVID-19 in New York City, March 1-May 16, 2020. MedRxiv.
- 401 2020:2020.06.27.20141689.

- 402 17. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus
- 403 disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669-77.
- 404 18. Green MS, Swartz N, Nitzan D, Peer V. The male excess in case-fatality rates
- 405 for COVID-19. A meta-analytic study of the age-related differences and consistency
- 406 over six countries. MedRxiv. 2020:2020.06.11.20128439.
- 407 19. Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, et al. Asymptomatic SARS-
- 408 CoV-2 infections: a living systematic review and meta-analysis. MedRxiv.
- 409 2020:2020.04.25.20079103.
- 410 20. Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections
- 411 with COVID-19. J Microbiol Immunol Infect. 2020.
- 412 21. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in
- 413 patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect
- 414 Dis. 2020;94:91-5.
- 415 22. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al.
- 416 Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-
- 417 analysis. Travel Med Infect Dis. 2020;34:101623.
- 418 23. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with
- 419 SARS-CoV-2 infection: A single arm meta-analysis. J Med Virol. 2020;92(6):612-7.
- 420 Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory 24.
- 421 dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus
- 422 disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol.
- 423 2020;277(8):2251-61.
- 424 25. Mao L, Wang M, Chen S, et al. Neurological Manifestations of Hospitalized
- 425 Patients with COVID-19 in Wuhan, China: a retrospective case series study. MedRxiv.
- 426 2020:2020.02.22.20026500.

- 427 Suresh Kumar VC, Mukherjee S, Harne PS, et al. Novelty in the gut: a 26.
- 428 systematic review and meta-analysis of the gastrointestinal manifestations of COVID-
- 429 19. BMJ Open Gastroenterol. 2020;7(1).
- 430 27. Parasa S, Desai M, Thoguluva Chandrasekar V, et al. Prevalence of
- 431 Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus
- 432 Disease 2019: A Systematic Review and Meta-analysis. JAMA Netw Open.
- 433 2020;3(6):e2011335.
- 434 Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal Manifestations of 28.
- 435 SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort:
- 436 Systematic Review and Meta-analysis. Gastroenterology. 2020;159(1):81-95.
- 29. 437 Ministerio de Sanidad – Consejo Interterritorial del Sistema Nacional de Salud –
- 438 Instituto de Salud Carlos III. Estudio ENE-COVID: informe final. Estudio nacional de
- 439 sero-epidemiologia de la infección por SARS-CoV-2 en España. Madrid 2020 [cited
- 440 2020 07/26]; Available from: https://www.mscbs.gob.es/ciudadanos/ene-
- 441 covid/docs/ESTUDIO ENE-COVID19 INFORME FINAL.pdf.
- 442 30. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported
- 443 symptoms to predict potential COVID-19. Nat Med. 2020;26(7):1037-40.
- 444 31. Sudre CH, Lee K, Ni Lochlainn M, et al. Symptom clusters in Covid19: A
- 445 potential clinical prediction tool from the COVID Symptom study app. MedRxiv.
- 446 2020:2020.06.12.20129056.

Table 1. Distribution of the study sample according to sociodemographic characteristics and region. The EPICOVID19 study, third wave.

	Sample distribution		
	Number	%	
Region			
Northeast	9982	31.3%	
North	5180	16.3%	
Central-West	3603	11.3%	
Southeast	8021	25.1%	
South	5083	16.0%	
Sex			
Female	18646	58.5%	
Male	13223	41.5%	
Age (years)			
0-4	637	2.0%	
5-9	862	2.7%	
10-19	2789	8.8%	
20-29	4965	15.6%	
30-39	4999	15.7%	
40-49	5078	15.9%	
50-59	5032	15.8%	
60-69	4234	13.3%	
70+	3273	10.3%	
Color/ethnicity			
White	11442	36.7%	
Brown	14131	45.4%	
Black	4264	13.7%	
Asian	897	2.9%	
Indigenous	429	1.4%	
Schooling			
Primary or less	11417	39.3%	
Secondary	11363	39.1%	
University or higher	6275	21.6%	
Wealth quintiles			
Poorest	7668	24.1%	
2nd	5809	18.2%	
3rd	6334	19.9%	
4th	6214	19.5%	
Richest	5844	18.3%	

Table 2. Prevalence of symptoms among subjects with positive and negative antibody tests for SARS-CoV-2, and prevalence ratios. The EPICOVID19 study, third wave.

Symptom	Prevalence		_	959	% CI
	Positive	Negative	Prevalence ratio	Lower bound	Upper bound
Headaches	58.0	35.5	1.6	1.5	1.8
Change in smell or taste	56.5	9.1	6.2	5.6	6.8
Fever	52.1	12.2	4.3	3.9	4.7
Cough	47.7	22.2	2.1	1.9	2.4
Myalgia	44.1	15.7	2.8	2.5	3.1
Sore throat	33.8	16.6	2.0	1.8	2.3
Diarrhea	25.6	11.7	2.2	1.9	2.5
Difficulty breathing	23.1	9.4	2.5	2.1	2.8
Shivering	20.5	6.1	3.3	2.9	3.9
Palpitation	20.0	10.5	1.9	1.6	2.2
Vomiting	9.5	4.0	2.4	1.9	3.0

Figure 1. Distribution of the number of symptoms in individuals positive and negative for antibodies for SARS-CoV-2. The EPICOVID19 study, third wave.





Figure 2. Mean number of symptoms and percent asymptomatic in subjects positive for antibodies against SARS-CoV-2, according to sociodemographic characteristics. The EPICOVID19 study, third wave.

Notes: diamonds represent the main Y axis for the mean number of symptoms (with their respective 95% CI). The bars represent the secondary Y axis for the prevalence of asymptomatic subjects.



465

466

467

468 469

470

Figure 3 – Conditional inference tree of the association between symptoms (predictors) and seroprevalence for SARS-CoV-2. The EPICOVID19 study, third wave.

474

475 476 477

478

481

482

The area of the rectangles corresponds to the proportion of the population contained in each node.

